A Platform Study of RAS(ON) Inhibitors in Patients with Gastrointestinal Solid Tumors
Categories (click each to see list of all clinical trials associated with that category): GI (ONC), Pancreatic Cancer Center of Excellence - PCCE (ONC)
Current Status: Not open
Phase: I/II (Cancer Control)
Principal Investigator: Klute, Kelsey
Contact Information:
Monica Davis
mondavis@unmc.edu
Eligibility: https://clinicaltrials.gov/study/NCT06445062?term=NCT06445062&rank=1&tab=table
Summary
Primary objectives: Evaluate the safety and tolerability in the study population characterized by incidence, abnormal laboratory assessments, severity, and seriousness of adverse events in relation to the study treatment. Number of participants with dose limiting toxicities
Secondary Objectives: Blood concentration of RMC-6236 and RMC-9805 over time; Overall Response Rate per RECIST v1.1; Duration of Response per RECIST v1.1; Incidence of Response per RECIST v1.1; Time to Response per RECIST v1.1; Progression Free Survival per RECIST v1.1; Overall Survival